Bitopertin Delivers 3.5 Years of Sun Tolerance in EPP Trial Patient

After three and a half years on bitopertin — including more than two years of open-label extension and expanded access — one erythropoietic protoporphyria (EPP) patient walked onto a beach with his family without full protective gear for the first time in his life.

He got a real sunburn. He didn't mind.

"A porphyria phototoxic reaction is far worse," Mr. Willis said, comparing the two experiences in a Dermatology Times patient-journey conversation with Dr. Bonkovsky. The episode, "EPP Patient Journey: Oral Therapies and Regaining Freedom in the Sun," walks through nearly 15 years of therapies Mr. Willis has tried and asks the practical question every clinician managing EPP should be asking: what do the newer oral agents actually change for patients day to day?

Dersimelagon: Consistent Pigmentation, Less Mental Load

Mr. Willis first joined a placebo-controlled trial of dersimelagon, a small-molecule melanocortin-1 receptor agonist. Its mechanism mirrors afamelanotide: it increases skin pigment and reduces photosensitivity. Mr. Willis became much darker than baseline, so he knew he had received active drug rather than placebo.

That pigmentation mattered. He liked the effect's consistency — no start-up periods, no cooling-down gaps between implants as he had experienced before. The steadiness eased the mental strain of managing EPP and gave him the confidence to be more aggressive about sun exposure.

For practitioners, that is the practical takeaway. A consistent oral effect removes the cycle of protection waxing and waning around implant schedules, which patients experience as cognitive burden as much as physical risk.

Bitopertin: A Different Mechanism, A Different Trade-off

Next came the Phase 3 trial of bitopertin. Dr. Bonkovsky explained the mechanism plainly: the drug inhibits the glycine-1 transporter, reducing glycine uptake into developing red cells and cutting off substrate for the first step of heme synthesis.

There were early concerns about anemia and other adverse effects. Mr. Willis experienced none of them. His only issues were mild dry skin and dizziness lasting 15 to 20 minutes after his first dose — transient, tolerable, and never recurring in a way that disrupted his life.

One difference stands out. Bitopertin produced no pigmentation, so Mr. Willis had no visible cue telling him the drug was working. Without that confidence signal, he committed to pushing his limits anyway. He received active drug, and the gamble paid off across three and a half years of benefit.

Which Drug Won?

Asked directly which therapy has been best over his nearly 15-year journey, Mr. Willis credited bitopertin as easy and exceptionally effective. He values the pigmentation he gained from dersimelagon. But on bitopertin, he develops only a farmer's tan and a hat-band tan — ordinary sun exposure marks, not drug-induced darkening — and that has been enough for a gear-free beach trip.

Dr. Bonkovsky confirmed Mr. Willis has tolerated the drug well throughout.

The comparison is instructive for anyone counseling EPP patients on trial options. Dersimelagon offers a visible, consistent pigment effect that reassures patients psychologically. Bitopertin offers durable photoprotection through heme-pathway modulation, with a tolerability profile that in this patient amounted to a single dizzy spell and mild dry skin.

What Comes Next

The series continues with "EPP Patient Case: Laboratory Findings and Commitment to Clinical Research," which reviews Mr. Willis's laboratory findings and explores why he chose to keep participating in research after so many years. For clinicians tracking emerging EPP options, that follow-up may round out the clinical picture these two oral agents have begun to sketch.